Mounjaro (tirzepatide) / Eli Lilly, Cipla, Aspen Pharma - LARVOL DELTA

Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization (AAD 2026) - "The treatment cohort included patients who initially used semaglutide, liraglutide, exenatide, dulaglutide, or tirzepatide after 2017. Treated patients were matched 1:1 with non-treated controls based on age, sex, race, type 2 diabetes, and congestive heart failure using propensity score matching...The treatment cohort had a significantly increased risk of developing all alopecia diagnoses (p < 0.0001), including the development of alopecia areata, androgenic alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, and folliculitis decalvans. These findings suggest GLP-1 and GLP-1/GIP agonists may significantly increase the risk of developing scarring and non-scarring alopecia."

Alopecia • Cardiovascular • Congestive Heart Failure • Dermatopathology • Diabetes • Fibrosis • Heart Failure • Hypertension • Immunology • Lichen Planus • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of GLP-1 and Dual GLP-1/GIP Receptor Agonists on Inflammatory Outcomes in Atopic Dermatitis: A Real-World Cohort Study (AAD 2026) - "Background: GLP-1 receptor agonists are established injectable therapies used in diabetes and obesity... These results support prior reports that GLP-1 receptor agonists reduce skin inflammation in AD. By attenuating NF-κB signaling and suppressing TNF-α, IL-6, and IL-17, GLP-1 agonists reduce inflammation. GIP signaling in tirzepatide may enhance this effect by decreasing adipose inflammation and limiting immune activation."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Obesity • Pruritus • Urticaria • IL17A • IL6 • TNFA

GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions (AAD 2026) - "Several patients (42%) experienced over three comorbidities, with diabetes, obesity, and hypertension being most common...Out of total alopecia reports, 700 (30.2%) were associated with semaglutide, 534 (23.1%) with liraglutide, 492 (21.3%) with tirzepatide, 304 (13.1%) with dulaglutide, and 284 (12.3%) with exenatide...GLP-1 RAs are associated with various dermatologic AEs, ranging from mild rashes to autoimmune disease. Increased recognition can improve diagnostic accuracy and guide safe therapeutic substitutions."

Alopecia • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

Dermatological effects of GLP-1 receptor agonists: A literature review (AAD 2026) - "Glucagon-like peptide-1 (GLP-1) receptor agonists have become an increasingly common class of medications for the management of type 2 diabetes mellitus and obesity...Improvement in psoriasis was reported with liraglutide, semaglutide, and exenatide...Our review demonstrates the dual nature of the dermatological effects of these medications. Clinicians should be made aware of these effects and monitor patients when prescribing GLP-1 receptor agonists."

Review • Acne Vulgaris • Alopecia • Atopic Dermatitis • Bullous Pemphigoid • Constipation • Dermatopathology • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Obesity • Pruritus • Psoriasis • Type 2 Diabetes Mellitus • Vasculitis

Dermatologic side effects of GLP-1 receptor agonists: A Cross-sectional Analysis (AAD 2026) - "Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the management of diabetes and obesity, with gastrointestinal side effects being the most commonly reported...Search terms included: GLP-1 Receptor Agonist, Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Albiglutide... Dermatologic AEs due to GLP-1 RAs use are relatively uncommon. Injection-site reactions represent the most frequent cutaneous complication, while alopecia, dermatitis, and urticaria are rarely reported. Proactively anticipating and addressing these dermatologic AEs are essential to optimizing patient care and counseling."

Adverse events • Alopecia • Dermatitis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

Impact of GLP-1 and GLP-1/GIP Agonists on Health Care Utilization in Individuals with Psoriasis: A Retrospective Cohort Analysis (AAD 2026) - "The treatment cohort included patients receiving semaglutide, liraglutide, or tirzepatide within one year of psoriasis diagnosis. Patients were matched 1:1 with non-treated controls based on age, sex, race, ethnicity, BMI, type 2 diabetes, congestive heart failure, and systemic psoriasis therapies using propensity score matching...The treated cohort averaged 8.87 hospitalizations and 2.53 ER visits per patient versus 13.70 and 3.14, respectively, in controls. These findings suggest GLP-1 and GLP-1/GIP agonists may reduce healthcare resource utilization in psoriasis, potentially reflecting improved disease control and financial burden."

HEOR • Retrospective data • Cardiovascular • Congestive Heart Failure • Dermatology • Dermatopathology • Diabetes • Heart Failure • Immunology • Metabolic Disorders • Psoriasis • Type 2 Diabetes Mellitus • IL12A • IL17A • IL23A

Risk of New-Onset Hair Loss with Semaglutide and Tirzepatide: A Retrospective Cohort Study (AAD 2026) - "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity...A metformin-treated, GLP-1RA–naïve cohort served as the comparator...These findings align with prior pharmacovigilance reports and highlight a potential drug-related effect. Clinicians should consider counseling patients regarding hair loss risk, particularly in the context of rapid weight reduction."

Retrospective data • Alopecia • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Concomitant therapy with ixekizumab plus tirzepatide in adults with psoriatic arthritis and overweight or obesity demonstrated superior disease control compared to ixekizumab alone: results from the Ph3b TOGETHER-PsA trial (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Association of GLP-1 Therapy with Reduced Biologic Initiation in Hidradenitis Suppurativa: A Retrospective Cohort Study (AAD 2026) - "Objective To assess whether GLP-1 therapy is associated with initiation of biologic treatment in patients with HS and obesity...The primary outcome was initiation of an HS-approved biologic (adalimumab, secukinumab, or bimekizumab) within three years...Conclusions In this large real-world cohort, GLP-1 therapy was associated with substantially reduced risk of biologic initiation in HS. These findings support further investigation of metabolic therapy as a potential disease-modifying strategy."

Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Obesity

The Effect of Specific GLP-1RAs on Wound Healing after Mohs Surgery in Overweight Non-Diabetic Patients (AAD 2026) - "No differences were observed for liraglutide, dulaglutide, exenatide, or tirzepatide. Conclusion Prospective studies are needed to evaluate the biomechanism and effects of GLP-1RAs in the wound healing process in non-diabetic individuals following MMS."

Clinical • Surgery • Fibrosis • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Impact of GLP-1 Receptor Agonists in Hormone Receptor-Positive Breast Cancer Patients Receiving CDK4/6 Inhibitors (HOPA 2026) - "Three cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors- abemaciclib, palbociclib, and ribociclib- have been approved by the United States Food and Drug Administration as first-line treatment for advanced or metastatic HR+, HER2- breast cancer...Obesity and type 2 diabetes, present in approximately 40% of U.S. adults, are associated with increased breast cancer risk, recurrence, and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, tirzepatide, dulaglutide, exenatide and liraglutide, are increasingly prescribed for these comorbidities due to their efficacy in weight reduction, glycemic control, and cardiovascular risk mitigation... Data collection and analysis are in progress."

Clinical • Breast Cancer • Diabetes • Eye Cancer • Genetic Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Metabolic Disorders • Obesity • Oncology • Retinal Disorders • Solid Tumor • Type 2 Diabetes Mellitus • HER-2

Tirzepatide during Ramadan in people with obesity without diabetes: A critical knowledge gap. (PubMed, Br J Clin Pharmacol) - No abstract available

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects. (PubMed, Br J Clin Pharmacol) - "Using FDA regulatory data, we compared GLP-1 RAs, GLP-1/GIP dual agonists and non-GLP-1 weight loss agents, finding the greatest weight reductions with tirzepatide and liraglutide. While efficacy outcomes were favourable, safety signals were limited by small sample sizes. Expanded real-world evidence is needed to better characterize long-term safety."

Journal • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. (PubMed, Int J Mol Sci) - "Comparative discussion of semaglutide, liraglutide, and tirzepatide highlights agent-specific pharmacokinetics and emerging clinical data linking GLP-1RA therapy to sleep outcomes, particularly obstructive sleep apnea. Finally, we outline translational opportunities for chronotherapy and precision medicine, positioning GLP-1RAs as integrative tools for metabolic and sleep-related disease rather than purely weight-centric therapies. We propose that GLP-1 receptor agonists may function as chronometabolic modulators, with potential implications for personalized chronopharmacological strategies in metabolic disease."

Journal • Review • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis. (PubMed, PLoS One) - "Tirzepatide is associated with an increased risk of GIAEs, particularly among patients with T2DM, males, older adults, and those using concomitant medications. FAERS-based real-world evidence complements clinical trial data and highlights the need for individualized patient monitoring and management strategies."

Adverse events • Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. (PubMed, J Clin Med) - "Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes in addition to other conditions such as obesity... This study utilized the publicly available FDA Adverse Event Reporting System (FAERS) to obtain AE reports related to exenatide, tirzepatide, dulaglutide, liraglutide, and semaglutide from 2005 to 2024...Clinicians should remain vigilant and consider eye care referrals when indicated. Further research is needed to validate these associations and clarify underlying mechanisms."

Adverse events • Journal • Review • Cataract • Diabetes • Diabetic Retinopathy • Genetic Disorders • Metabolic Disorders • Obesity • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition. (PubMed, Int J Mol Sci) - "Prior therapies (glucocorticoids, methotrexate, leflunomide) achieved suboptimal control...This case adds to the limited literature supporting JAK inhibition as a targeted option for refractory MRH, including multisystem disease with pulmonary involvement. Systematic evaluation of efficacy, durability, and safety is warranted."

Journal • Diabetes • Hepatology • Immunology • Infectious Disease • Interstitial Lung Disease • Metabolic Disorders • Oncology • Pneumonia • Primary Biliary Cholangitis • Pulmonary Disease • Respiratory Diseases

Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults. (PubMed, Diabetes Obes Metab) - "In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF, compared with semaglutide, with a similar safety profile."

Journal • Real-world evidence • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity

Prevalence of Obesity Medications in the Military Health System: An Update from 2022. (PubMed, Mil Med) - "Obesity medication utilization in the MHS increased modestly since 2018 but remains low relative to disease prevalence, particularly among active-duty and minority beneficiaries. Recent TRICARE coverage changes may further shape access and prescribing patterns, though their downstream effects on health outcomes, readiness, and costs remain uncertain. These findings highlight ongoing knowledge gaps regarding the optimal, sustainable use of OM in the MHS and underscore the need for MHS-specific effectiveness, safety, and cost-effectiveness data to inform evidence-based, readiness-aligned obesity care strategies."

Journal • Cardiovascular • Coronary Artery Disease • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. (PubMed, J Diabetes Metab Disord) - "This review aims to evaluate the efficacy of tirzepatide as an adjunct to insulin therapy in adults with Type 1 diabetes mellitus (T1DM) and overweight or obesity, focusing on changes in glycemic control, body weight, body mass index (BMI), and insulin dose requirements...Larger randomized controlled trials are warranted to confirm these results and define optimal dosing and long-term safety. The online version contains supplementary material available at 10.1007/s40200-026-01880-0."

Journal • Retrospective data • Anorexia • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: LABORATORIOS INDUFAR

New trial • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

EFFECTS OF INCRETIN-BASED THERAPIES ON KIDNEY OUTCOMES IN OBESE PATIENTS WITHOUT DIABETES (ISN-WCN 2026) - "Consistent findings across frequentist and Bayesian analyses strengthened result robustness.Conclusion Among obese adults without diabetes, Retatrutide produced the largest improvement in eGFR, while Semaglutide and Retatrutide most effectively reduced UACR. Incretin-based therapies may confer renal benefits beyond glycemic control, supporting further evaluation of dual GLP-1/GIP agonists in nondiabetic obesity-related kidney disease."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Genetic Disorders • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • RAS

NORMAL PROTEIN CATABOLIC RATE (NPCR) AS A PREDICTOR OF WEIGHT LOSS IN HEMODIALYSIS PATIENTS TREATED WITH TIRZEPATIDE (ISN-WCN 2026) - "Neither serum phosphorus nor potassium levels correlated with weight change.Conclusion nPCR serves as a sensitive marker for predicting weight change in HD patients treated with tirzepatide. Continuous monitoring of nPCR may enable early identification of appetite loss and facilitate safe DW adjustment, thereby preventing complications such as pulmonary congestion or pleural effusion during GLP-1/GIP therapy in the HD population."

Clinical • Anorexia • Diabetes • Metabolic Disorders • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

EARLY POSTTRANSPLANT GLP-1 AGONISTIC INTERVENTION AND GRAFT KIDNEY FUNCTION IN TRANSPLANT RECIPIENTS WITH TYPE 2 DIABETES (ISN-WCN 2026) - "Of those, 75 KTRs were GLP-1 users (duraglutide; 23, liraglutide; 31, semaglutide; 19, tirzepatide; 2), whereas 65 were non-users at week 3 after KTX...Early posttransplant GLP-1 receptor agonistic intervention may help slow progressive kidney disease and enhance graft kidney survival. Prospective randomized controlled trials are rigorously needed."

Clinical • Post-transplantation • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Transplantation • Type 2 Diabetes Mellitus

ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS (ISN-WCN 2026) - P3 | "A significantly smaller decline in eGFR was observed with pooled TZP (-1.6±0.5 ml/min per 1.73m2) compared to placebo (-5.5±1.0 ml/min per 1.73m2) after 176 weeks (estimated treatment difference (ETD) of 3.9 ml/min per 1.73m2, p<0.001). A greater percentage decrease in UACR was observed with pooled TZP (-15.8±2.9%) compared to placebo (-3.9±6.4%) after 176 weeks (ETD of -12.4%, p=0.078).Conclusion In SURMOUNT-1 participants with prediabetes, overweight or obesity, and preserved eGFR at baseline, use of TZP was associated with an attenuated decline of eGFR over 3 years with a nonsignificant trend toward UACR reduction.This abstract was also submitted for the American Diabetes Association – 85th Annual Scientific Sessions, Chicago, IL, USA, in 2025.I have potential conflict of interest to disclose.Yusuke Takahashi is an employee of Eli Lilly Japan K.K. and a minor stockholder of Eli Lilly and Company.I did not use generative AI and AI-assisted..."

Chronic Kidney Disease • Diabetic Nephropathy • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus